Study to test the Ethniq Lung Detox Bars and Paste for Better Lung Health

An Open-Label, Two-Arm, Multi-Centered Clinical Study To Evaluate The Safety And Efficacy Of Ethniq Lung Detox Bars And Paste In Subjects For Lung Health. - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083237

Enrollment

200

Registered

2025-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R05- Cough Health Condition 2: R060- Dyspnea Health Condition 3: R062- Wheezing

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 to 65 years 2. Respiratory symptoms include participants presenting with mild to moderate symptoms such as coughing, wheezing, or shortness of breath. 3. Participants with mild to moderate asthma should have an ACT score of 16 or higher and an FEV1 of 60 percent or higher to ensure the inclusion of controlled asthma cases. 4. Eligible participants include those with chronic cough, bronchitis, mild asthma, or those seeking lung detoxification support. 5. Participants must be willing to provide informed consent and adhere to the study protocol.

Exclusion criteria

Exclusion criteria: 1. Diagnosed with severe chronic respiratory diseases such as COPD or severe asthma requiring urgent medical care or long-term medication. 2. Respiratory conditions that required hospitalization within the past six months. 3. ACT score below 16, GOLD Stage 3 or 4 for COPD, or dependency on systemic steroids or oxygen therapy. 4. Severe cardiovascular diseases, including a heart attack or stroke within the past year. 5. Known allergy or hypersensitivity to any ingredient in the Lung Detox Bars or Paste. 6. Pregnant or breastfeeding women. 7. Severe mental illness or conditions that may affect compliance with the study protocol. 8. Use of investigational drugs or devices within 30 days prior to the study. 9. Severe comorbidities that may interfere with study outcomes or participant safety.

Design outcomes

Primary

Measure	Time frame
Improvement in Lung Function (Relative to Baseline): PFT Parameters: Increase in lung volume, vital capacity, and tidal volume.Spirometry Metrics: Improvement in FEV1, FVC, and FEV1/FVC ratio. Timepoint: Day 0, Day 30, Day 45, Day 60 and Day 90	—

Secondary

Measure	Time frame
1. Chronic Cough: Reduction in severity and frequency, as measured by the Leicester Cough Questionnaire and Visual Analog Scale (VAS). 2. Bronchitis: Improvement in bronchial comfort and reduction in sputum production. 3. Asthma: Improved symptom control, as assessed by the Asthma Control Test (ACT) and spirometry metrics (e.g., FEV1). 4. Lung Detox: Improved blood oxygen saturation (SpO2) and participant-reported detox-related outcomes. Timepoint: Day 0, Day 30, Day 45, Day 60 and Day 90	—

Measure

Time frame

1. Chronic Cough: Reduction in severity and frequency, as measured by the Leicester Cough Questionnaire and Visual Analog Scale (VAS). 2. Bronchitis: Improvement in bronchial comfort and reduction in sputum production. 3. Asthma: Improved symptom control, as assessed by the Asthma Control Test (ACT) and spirometry metrics (e.g., FEV1). 4. Lung Detox: Improved blood oxygen saturation (SpO2) and participant-reported detox-related outcomes. Timepoint: Day 0, Day 30, Day 45, Day 60 and Day 90

—

Countries

India

Contacts

Public ContactMs Arpita Malgi

Samahitha Research Solutions

satyalm@samahitha.com09739001749

Outcome results